Maribavir is primarily used as an antiviral medication, specifically for the treatment of cytomegalovirus (CMV) infections. It is particularly effective in patients who have undergone organ transplants, as they are at a higher risk of CMV reactivation due to immunosuppressive therapy. Maribavir works by inhibiting the viral DNA replication process, thereby preventing the virus from multiplying and spreading.

In clinical settings, it is often prescribed for patients who have developed resistance to other antiviral drugs, such as ganciclovir, valganciclovir, foscarnet, or cidofovir. Its targeted mechanism of action makes it a valuable option for managing difficult-to-treat CMV infections, reducing the risk of complications such as organ rejection or severe systemic illness. Additionally, maribavir is being studied for its potential use in other viral infections, expanding its therapeutic applications in the future.